Q32 Historical Financial Ratios

QTTB Stock

26.91 0.01 0.04%

Q32 Bio is promptly reporting on over 73 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 43.26, Invested Capital of 0.0, Average Payables of 7.3 M or Stock Based Compensation To Revenue of 0.18 will help investors to properly organize and evaluate Q32 Bio financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.

About Q32 Financial Ratios Analysis

Q32 BioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Q32 Bio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Q32 financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Q32 Bio history.

Q32 Bio Financial Ratios Chart

At present, Q32 Bio's Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Research And Ddevelopement To Revenue is expected to grow to 56.32, whereas Price To Sales Ratio is forecasted to decline to 28.89.

Price To Sales Ratio Days Sales Outstanding Average Payables Inventory Turnover Payout Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Q32 Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Q32 Bio sales, a figure that is much harder to manipulate than other Q32 Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Payout Ratio

Payout Ratio is the proportion of Q32 Bio earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of Q32 Bio dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating Q32 Bio is paying out more in dividends than it makes in net income.

Most ratios from Q32 Bio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Q32 Bio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.At present, Q32 Bio's Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Research And Ddevelopement To Revenue is expected to grow to 56.32, whereas Price To Sales Ratio is forecasted to decline to 28.89.

	2022	2023	2024 (projected)
Payables Turnover	1.81	0.18	0.17
Days Of Inventory On Hand	245.77	221.19	232.25

Payables Turnover Days Of Inventory On Hand

Q32 Bio fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		-0.02	0.63	0.62	0.31	-0.41	0.3	-0.03	-0.02	0.99	-0.48	0.03	0.43	-0.37	-0.43	0.38	0.3	0.89	0.47	0.0	-0.19	0.0	-0.36	0.16	0.03	0.0
Ptb Ratio	-0.02		-0.01	-0.42	0.43	0.63	0.36	0.4	1.0	0.05	0.62	-0.63	0.49	0.78	-0.49	-0.63	0.36	0.28	-0.71	-0.84	-0.35	-0.7	0.43	0.65	-0.51	-0.85
Days Sales Outstanding	0.63	-0.01		0.49	-0.19	-0.37	-0.15	-0.04	-0.01	0.6	-0.4	-0.35	-0.2	-0.37	0.2	-0.14	-0.15	0.58	0.3	0.01	-0.18	0.01	0.16	-0.04	-0.39	0.01
Book Value Per Share	0.62	-0.42	0.49		-0.08	-0.71	-0.09	0.13	-0.42	0.56	-0.81	0.04	0.19	-0.75	-0.2	0.5	-0.09	0.47	0.81	0.36	-0.18	0.32	-0.29	-0.14	-0.02	0.37
Free Cash Flow Yield	0.31	0.43	-0.19	-0.08		0.52	0.93	0.51	0.43	0.38	0.4	0.34	0.8	0.47	-0.77	0.22	0.93	0.47	0.07	-0.28	-0.33	-0.17	-0.53	0.14	0.46	-0.29
Operating Cash Flow Per Share	-0.41	0.63	-0.37	-0.71	0.52		0.45	0.31	0.63	-0.3	0.97	-0.03	0.28	0.95	-0.26	-0.57	0.45	-0.06	-0.62	-0.28	0.05	-0.12	0.25	-0.02	0.07	-0.31
Average Payables	0.3	0.36	-0.15	-0.09	0.93	0.45		0.47	0.36	0.36	0.34	0.37	0.73	0.41	-0.72	0.27	1.0	0.42	0.11	-0.24	-0.31	-0.15	-0.57	0.18	0.47	-0.24
Capex To Depreciation	-0.03	0.4	-0.04	0.13	0.51	0.31	0.47		0.4	0.07	0.11	0.03	0.41	0.36	-0.39	0.06	0.47	0.27	0.15	-0.43	-0.83	-0.38	-0.22	0.31	0.11	-0.44
Pb Ratio	-0.02	1.0	-0.01	-0.42	0.43	0.63	0.36	0.4		0.05	0.62	-0.63	0.49	0.78	-0.49	-0.63	0.36	0.28	-0.71	-0.84	-0.35	-0.7	0.43	0.65	-0.51	-0.85
Ev To Sales	0.99	0.05	0.6	0.56	0.38	-0.3	0.36	0.07	0.05		-0.39	0.05	0.47	-0.25	-0.47	0.34	0.36	0.95	0.43	-0.05	-0.24	-0.03	-0.35	0.17	0.07	-0.05
Free Cash Flow Per Share	-0.48	0.62	-0.4	-0.81	0.4	0.97	0.34	0.11	0.62	-0.39		-0.1	0.18	0.93	-0.17	-0.65	0.34	-0.18	-0.74	-0.28	0.2	-0.13	0.35	-0.02	-0.01	-0.3
Roic	0.03	-0.63	-0.35	0.04	0.34	-0.03	0.37	0.03	-0.63	0.05	-0.1		0.01	-0.2	0.02	0.73	0.37	-0.08	0.58	0.54	0.08	0.49	-0.83	-0.52	0.99	0.55
Inventory Turnover	0.43	0.49	-0.2	0.19	0.8	0.28	0.73	0.41	0.49	0.47	0.18	0.01		0.31	-1.0	0.18	0.73	0.56	0.02	-0.3	-0.22	-0.19	-0.3	0.37	0.11	-0.31
Net Income Per Share	-0.37	0.78	-0.37	-0.75	0.47	0.95	0.41	0.36	0.78	-0.25	0.93	-0.2	0.31		-0.3	-0.61	0.41	0.0	-0.75	-0.54	-0.11	-0.39	0.33	0.28	-0.08	-0.56
Days Of Inventory On Hand	-0.43	-0.49	0.2	-0.2	-0.77	-0.26	-0.72	-0.39	-0.49	-0.47	-0.17	0.02	-1.0	-0.3		-0.17	-0.72	-0.56	-0.01	0.3	0.21	0.19	0.27	-0.38	-0.08	0.31
Payables Turnover	0.38	-0.63	-0.14	0.5	0.22	-0.57	0.27	0.06	-0.63	0.34	-0.65	0.73	0.18	-0.61	-0.17		0.27	0.12	0.79	0.32	-0.21	0.19	-0.92	-0.09	0.7	0.34
Average Inventory	0.3	0.36	-0.15	-0.09	0.93	0.45	1.0	0.47	0.36	0.36	0.34	0.37	0.73	0.41	-0.72	0.27		0.42	0.11	-0.24	-0.31	-0.15	-0.57	0.18	0.47	-0.24
Capex To Revenue	0.89	0.28	0.58	0.47	0.47	-0.06	0.42	0.27	0.28	0.95	-0.18	-0.08	0.56	0.0	-0.56	0.12	0.42		0.28	-0.17	-0.33	-0.11	-0.19	0.23	-0.03	-0.18
Cash Per Share	0.47	-0.71	0.3	0.81	0.07	-0.62	0.11	0.15	-0.71	0.43	-0.74	0.58	0.02	-0.75	-0.01	0.79	0.11	0.28		0.57	-0.18	0.49	-0.7	-0.42	0.52	0.58
Pocfratio	0.0	-0.84	0.01	0.36	-0.28	-0.28	-0.24	-0.43	-0.84	-0.05	-0.28	0.54	-0.3	-0.54	0.3	0.32	-0.24	-0.17	0.57		0.65	0.98	-0.2	-0.89	0.45	1.0
Capex To Operating Cash Flow	-0.19	-0.35	-0.18	-0.18	-0.33	0.05	-0.31	-0.83	-0.35	-0.24	0.2	0.08	-0.22	-0.11	0.21	-0.21	-0.31	-0.33	-0.18	0.65		0.68	0.3	-0.59	0.02	0.64
Pfcf Ratio	0.0	-0.7	0.01	0.32	-0.17	-0.12	-0.15	-0.38	-0.7	-0.03	-0.13	0.49	-0.19	-0.39	0.19	0.19	-0.15	-0.11	0.49	0.98	0.68		-0.12	-0.91	0.4	0.97
Days Payables Outstanding	-0.36	0.43	0.16	-0.29	-0.53	0.25	-0.57	-0.22	0.43	-0.35	0.35	-0.83	-0.3	0.33	0.27	-0.92	-0.57	-0.19	-0.7	-0.2	0.3	-0.12		0.11	-0.84	-0.21
Income Quality	0.16	0.65	-0.04	-0.14	0.14	-0.02	0.18	0.31	0.65	0.17	-0.02	-0.52	0.37	0.28	-0.38	-0.09	0.18	0.23	-0.42	-0.89	-0.59	-0.91	0.11		-0.44	-0.89
Roe	0.03	-0.51	-0.39	-0.02	0.46	0.07	0.47	0.11	-0.51	0.07	-0.01	0.99	0.11	-0.08	-0.08	0.7	0.47	-0.03	0.52	0.45	0.02	0.4	-0.84	-0.44		0.45
Ev To Operating Cash Flow	0.0	-0.85	0.01	0.37	-0.29	-0.31	-0.24	-0.44	-0.85	-0.05	-0.3	0.55	-0.31	-0.56	0.31	0.34	-0.24	-0.18	0.58	1.0	0.64	0.97	-0.21	-0.89	0.45

Click cells to compare fundamentals

Q32 Bio Account Relationship Matchups

Q32 Bio fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	523.31	191.83	5.92	10.87	30.41	28.89
Ptb Ratio	3.37	2.64	(2.26)	(0.55)	0.48	0.46
Days Sales Outstanding	87.64	54.03	9.77	58.39	67.15	58.23
Book Value Per Share	110.48	76.84	(29.05)	(40.99)	22.72	43.26
Free Cash Flow Yield	(0.11)	(0.13)	(0.19)	(0.16)	(2.74)	(2.61)
Operating Cash Flow Per Share	(39.04)	(36.98)	(10.74)	(3.44)	(29.95)	(31.45)
Capex To Depreciation	3.46	0.42	3.34	6.72	0.39	0.37
Pb Ratio	3.37	2.64	(2.26)	(0.55)	0.48	0.46
Ev To Sales	491.03	117.08	5.12	11.0	(2.42)	(2.3)
Free Cash Flow Per Share	(48.37)	(38.45)	(10.79)	(4.22)	(30.02)	(31.52)
Roic	(0.43)	(0.66)	0.44	0.42	(1.61)	(1.53)
Net Income Per Share	(44.41)	(50.46)	(12.23)	(13.42)	(35.16)	(36.91)
Research And Ddevelopement To Revenue	53.66	37.15	0.88	5.38	53.63	56.32
Capex To Revenue	13.11	1.38	0.004622	0.37	0.2	0.19
Cash Per Share	112.14	85.25	25.96	57.99	25.72	24.44
Pocfratio	(9.54)	(5.49)	(6.1)	(6.6)	(0.37)	(0.38)
Capex To Operating Cash Flow	(0.59)	(0.24)	(0.0396)	(0.004761)	(0.002369)	(0.002488)
Pfcf Ratio	(7.7)	(5.29)	(6.07)	(5.38)	(0.36)	(0.35)
Income Quality	0.77	0.88	0.73	0.26	0.85	0.52
Roe	(0.4)	(0.66)	0.42	0.33	(1.55)	(1.47)
Ev To Operating Cash Flow	(8.95)	(3.35)	(5.27)	(6.68)	0.0291	0.0305
Pe Ratio	(8.39)	(4.03)	(5.36)	(1.69)	(0.31)	(0.33)
Return On Tangible Assets	(0.33)	(0.49)	(1.07)	(0.69)	(0.37)	(0.39)
Ev To Free Cash Flow	(7.23)	(3.23)	(5.25)	(5.44)	0.029	0.0276
Earnings Yield	(0.12)	(0.25)	(0.19)	(0.59)	(3.21)	(3.05)
Net Debt To E B I T D A	0.52	1.66	0.32	(0.0216)	0.44	0.42
Current Ratio	21.54	9.69	4.71	0.81	7.25	9.7
Tangible Book Value Per Share	110.48	76.84	(29.05)	(40.99)	22.72	43.26
Receivables Turnover	4.17	6.76	37.37	6.25	5.63	9.79
Graham Number	332.26	295.36	89.41	111.27	134.05	141.63
Shareholders Equity Per Share	110.48	76.84	(29.05)	(40.99)	22.72	43.26
Capex Per Share	9.33	1.46	0.0511	0.78	0.071	0.0674
Graham Net Net	90.02	58.81	(14.18)	(1.84)	(46.83)	(44.49)
Revenue Per Share	0.71	1.06	11.06	2.09	0.36	0.34
Enterprise Value Over E B I T D A	(7.89)	(2.61)	(2.02)	(1.88)	0.0323	0.034

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:

How To Invest In Q32

Details

Is Q32 Stock a good investment?

Details

What is Q32 Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.50)

Revenue Per Share

(1.24)

The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Q32 Historical Financial Ratios

About Q32 Financial Ratios Analysis

Q32 Bio Financial Ratios Chart

Price To Sales Ratio

Average Payables

Inventory Turnover

Payout Ratio

Q32 Bio fundamentals Correlations

Q32 Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Q32 Bio fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Average Inventory	+ 1.0	Average Payables
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Sales	+ 0.99	Price To Sales Ratio
Roe	+ 0.99	Roic
Pfcf Ratio	+ 0.98	Pocfratio

Days Of Inventory On Hand	- 1.0	Inventory Turnover
Days Payables Outstanding	- 0.92	Payables Turnover
Income Quality	- 0.91	Pfcf Ratio
Ev To Operating Cash Flow	- 0.89	Income Quality
Income Quality	- 0.89	Pocfratio
Ev To Operating Cash Flow	- 0.85	Pb Ratio